Prior to her scientific training, Katia Nazmutdinova ran a video transfer services company in the States, which was sold for a profit in 2007 and exists to this day. She then studied human biology, while working part-time as a freelance writer, broadcast editor and a science tutor and obtained her MSci in Biological Sciences (UCL, 2013) and a PhD in Genetics of Rare Diseases (UCL, 2018). In her doctoral research she modelled a rare kidney disease using patient-derived cells, isolated from urine. There was huge potential in this new cell source and an opportunity to innovate, which resulted in Encelo, co-founded with Dr Natalie Grefenstette, who has a background in organic chemistry. Dr Katia Nazmutdinova is the driving force of Encelo, responsible for product development, the strategic direction of the company and liaising with prospective customers and partners.
Did you know?
While it might look like a plant-based food company, NotCo is in the data and AI business—and aims to disrupt R&D in many industries that use animal and plant ingredients.
Gilberto Loureiro grew up inspecting fabrics in a Portuguese textile factory. With Smartex, he and co-founders Antonio Rocha and Paulo Ribeiro are eliminating textile defects—and their enormous cost both to manufacturers and the environment.
Miranda Wang and Jeanny Yao have an uncanny talent for finding value where others see waste. Their plastics upcycling company, Novoloop, just raised an $21m Series A to prove it.
To find the future of food, you may have to look no further than Emeryville, CA, a small city by the San Francisco Bay, where Upside Foods has built a 53,000-square-foot production facility for cultivated meat, the first of its kind.
In a timeless dilemma for new parents, Radhika and her husband Bharath discovered early that their baby daughter was a fussy sleeper. The situation left them tired and frustrated; being effective at work became a challenge.
In December 2021 Prellis raised a $14.5 million Series B and has signed partnerships with pharmaceutical behemoths including Bristol Myers Squibb and Sanofi.
It was 2016, and Chiu Chau was on the ropes. He had pitched nearly 150 venture capital firms. No one would invest. Everyone doubted the startup with the open-source laboratory robot.
Adebayo (“Ade”) Alonge and Amy Kao, co-founders of RxAll had nvented a handheld scanner for detecting counterfeit prescription drugs—an illicit, multibillion-dollar industry that kills an estimated 1 million people annually globally and 100,000 in Africa.